ADAR1 CAPITAL MANAGEMENT LLC
Q2 2024 Form 13-F
AUSTIN, TEXAS
CIK 0001940272
· CRD 299694
· SEC-registered investment adviser
$529.7M Reported Value Total
ADAR1 CAPITAL MANAGEMENT, LLC reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $507,774,765, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
2 funds
· $1.3B gross asset value
Hedge Fund: $1.3B
Source: Form ADV filed 2026-03-31
Reported value
$529.7M
Quarter over quarter
-3.1%
Holdings
245
Top-10 concentration
58.2%
Key People
Form ADV owners & control persons
Daniel Pawel Schneeberger
MANAGING PARTNER
Stuart Knox Graham
COO
Stephen Thomas Scipione
HEAD OF OPERATIONS, CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2024 13F record
Q2 2024 13F filing summary
| Period of report | June 30, 2024 |
|---|---|
| Filed | August 13, 2024 |
| Form | 13F-HR |
| Reported value | $529.7M |
| Positions | 245 |
| Change in reported value | +20.2% |
| New positions | 63 |
| Exited positions | 57 |
| Position turnover | 39.7% |
| Top-10 concentration | 58.2% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
262 | $2.2B |
|
Q1 2026 13F
Filed May 18, 2026
|
290 | $1.7B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
249 | $1.4B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
197 | $1.1B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
199 | $652.1M |
|
Q1 2025 13F
Filed May 15, 2025
|
192 | $538.7M |
|
Q4 2024 13F
Filed Feb 13, 2025
|
195 | $500.4M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
258 | $614.9M |
|
Q2 2024 13F
Filed Aug 13, 2024
|
245 | $529.7M |
|
Q1 2024 13F
Filed May 15, 2024
|
239 | $440.8M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
150 | $279.8M |
Top 20 holdings · Q2 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | PTGX PROTAGONIST THERAPEUTICS INC | $55.6M | 10.49% |
| 2 | CYTK CYTOKINETICS INC | $46.3M | 8.73% |
| 3 | ROIV ROIVANT SCIENCES LTD | $43.9M | 8.28% |
| 4 | BOXX EA SERIES TRUST | $37.9M | 7.15% |
| 5 | BBIO BRIDGEBIO PHARMA INC | $32.0M | 6.05% |
| 6 | RPRX ROYALTY PHARMA PLC | $31.2M | 5.88% |
| 7 | KROS KEROS THERAPEUTICS INC | $25.1M | 4.74% |
| 8 | INSM P INSMED INC | $13.5M | 2.54% |
| 9 | IMVT IMMUNOVANT INC | $12.6M | 2.38% |
| 10 | ABUS ARBUTUS BIOPHARMA CORP | $10.2M | 1.92% |
| 11 | INSM C INSMED INC | $10.1M | 1.9% |
| 12 | MRK MERCK & CO INC | $9.4M | 1.77% |
| 13 | RZLT REZOLUTE INC | $8.9M | 1.68% |
| 14 | SLDB SOLID BIOSCIENCES INC | $8.1M | 1.52% |
| 15 | EWTX EDGEWISE THERAPEUTICS INC | $7.9M | 1.48% |
| 16 | PCSC PERCEPTIVE CAP SOLUTIONS COR | $7.5M | 1.42% |
| 17 | ASND ASCENDIS PHARMA A/S | $7.0M | 1.32% |
| 18 | TECX TECTONIC THERAPEUTIC INC | $5.9M | 1.11% |
| 19 | QURE UNIQURE NV | $5.5M | 1.03% |
| 20 | ABSI ABSCI CORPORATION | $5.2M | 0.99% |
Values as reported on the Q2 2024 Form 13F. Every position is in the holdings table below.